劲方医药-B：悉数行使超额配股权、稳定价格期结束

Core Insights - The company, Jinfang Pharmaceutical-B (02595), announced that the sole sponsor and overall coordinator has fully exercised the over-allotment option as of October 16, 2025, involving a total of 13.386 million H-shares, which represents approximately 15% of the total shares available for subscription before the exercise of any over-allotment options [1] - The over-allotment shares will be issued at a price of HKD 20.39 per H-share and will be used to cover the excess allocation in the international offering [1] - The stabilization period for the global offering ended on October 16, 2025, which is 30 days after the submission deadline for the Hong Kong public offering application [1]